Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.
about
Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRTComparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer.Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients.Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.Primary adenocarcinoma of the lung--histological subtypes and outcome after surgery, using the IASLC/ATS/ERS classification of lung adenocarcinoma.Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma.Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advancesGenomic mutations and histopathologic biomarkers in Y radioembolization for chemorefractory colorectal liver metastases
P2860
Q30834087-E4E03601-2022-4EB3-AC6C-0E68848A0242Q31152462-3777923A-9E1E-4BCF-ACEF-5D6C919CD502Q36382039-5757E0A7-7E98-4B78-B0C2-BB6E879F580FQ37672027-8D5801D8-24EC-4291-93AA-B3711F11DA5DQ38622803-5F1309A9-5D9B-42DF-BDC5-329447F7DE3AQ38853126-5CB92010-754F-4865-9FAD-376984296021Q38903804-E844E141-1CC2-4E84-B70C-DFCBF4BEACAAQ38937520-C3D3D98B-E21B-471B-A16F-B7039638EC4AQ40864750-ED304B55-470A-4FC8-A5DF-4CCA69E42CA0Q42242957-A871FE90-2B52-473E-B817-C62D56FE443EQ49716871-C335A12D-7F00-4B8C-9448-7B9B61467751Q55508864-7594D198-DC77-4CC2-B31D-226E1610C6A0Q57172947-25A239A5-13CF-4A9F-B6EC-7E5F24AE5389Q58727444-70243F24-CA3D-4481-90A1-7471C6E1B120
P2860
Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@ast
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@en
type
label
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@ast
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@en
prefLabel
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@ast
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@en
P2093
P2860
P1433
P1476
Outcomes by tumor histology an ...... ge non-small-cell lung cancer.
@en
P2093
Aileen B Chen
David J Sher
David Kozono
Elizabeth H Baldini
Fred H Hacker
Gretchen Hermann
John H Lewis
Paul J Catalano
Raymond H Mak
P2860
P356
10.1016/J.CLLC.2014.09.005
P407
P577
2014-09-30T00:00:00Z